Stock Details
BIIB is Biogen Inc.'s stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 288.60$. Average daily volumn in 3 months 1.23M. Market cap 41.77B

Stock symbol : BIIB. Exchange : NasdaqGS. Currency : USD
Lastest price : 290.08$. Total volume : 894.29k. Market state CLOSED
Click reload if you want to check the lastest price on market!!!

Biogen Inc. (BIIB)
Last Price

Previous Close291.92
Day Range289.94-295.89
Bid279.00 x 800
Ask290.66 x 2.2k
Average Volume1.23M
Market Cap41.77B
52 Week Range187.16-311.88
Trailing P/E14.91
Foward P/E18.37
Dividend (Yield %)N/A
Ex-Dividend DateN/A

Financial Details

According to Biogen Inc.'s financial reports the company's revenue in 2021 were 10.98B an decrease(-23.08%) over the years 2020 revenue that were of 13.44B. In 2021 the company's total earnings were 1.56B while total earnings in 2020 were 4B(-75%).

Loading ...


Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXAB... I, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Market Cap:
Total Assets:
Total Cash:

News about "Biogen Inc."

Analysts Update Their Estimates For Biogen Inc.

Source from : stocksregister - 22 hours ago

Biogen Inc. (NASDAQ:BIIB) concluded the trading at $290.08 on Friday, January 27 with a fall of -0.63% from its closing price on previous day. Taking a look at stock we notice that its last check on ...See details»


Biogen Inc. stock outperforms market despite losses on the day

Source from : MarketWatch - 4 days ago

Shares of Biogen Inc. dropped 0.02% to $291.88 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow ...See details»


Biogen Inc. stock outperforms market on strong trading day

Source from : MarketWatch - 3 days ago

Shares of Biogen Inc. BIIB inched 0.16% higher to $292.34 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average DJIA rising ...See details»

Biogen (BIIB) & Eisai's Lecanemab Secures EMA's MAA Acceptance

Source from : YAHOO!News - 1 days ago

Biogen (BIIB) and Eisai jointly announce that EMA accepts lecanemab's marketing authorization application (MAA) for the treatment of patients with early-stage Alzheimer's disease, for review.See details»


Why Biogen Inc. (BIIB) Could Beat Earnings Estimates Again

Source from : on MSN - 4 days ago

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Biogen Inc. (BIIB), which belongs to the ...See details»

Biogen Inc.

Source from : Wall Street Journal - 3 days ago

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...See details»

Biogen Inc. (BIIB) Stock Moves -0.02%: What You Should Know

Source from : Yahoo Finance - 4 days ago

Biogen Inc. (BIIB) closed at $291.88 in the latest trading session, marking a -0.02% move from the prior day. This change was narrower than the S&P 500's daily loss of 0.07%. Meanwhile, the Dow gained ...See details»


Former CEO says Biogen 'shot themselves in the foot' by deciding to charge $56,000 for its controversial Alzheimer's drug

Source from : Business Insider - 10 days ago

George Scangos, who ran Biogen from 2010 to 2016, said he believed the Alzheimer's drug worked but "they priced it way too high." ...See details»

What's Going On With Biogen Stock Today?

Source from : - 29 days ago

Biogen Inc BIIB shares traded higher Thursday morning before pulling back. Reports indicate that the FDA's process for approving Biogen's Alzheimer's drug Aduhelm was filled with "irregularities." ...See details»


EU regulator accepts for review Alzheimer's treatment from Eisai-Biogen

Source from : YAHOO!News - 2 days ago

The application to the EMA was based on results from a late-stage study that showed the drug slowed down the rate of cognitive decline in patients with early Alzheimer's by 27%, compared with a ...See details»

FDA Faulted for Working Improperly With Biogen Before Clearing Alzheimerโ€™s Drug

Source from : Wall Street Journal - 1 month ago

The U.S. Food and Drug Administration โ€œinappropriatelyโ€ collaborated with Biogen Inc. before approving its Alzheimerโ€™s treatment Aduhelm in 2021, a new report from House Democrats concluded ...See details»

Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know

Source from : Nasdaq - 10 days ago

Biogen Inc. (BIIB) closed the most recent trading day at $280.13, moving -1.18% from the previous trading session. This change lagged the S&P 500's daily loss of 0.76%. Meanwhile, the Dow lost 0. ...See details»

Biogen Inc.: Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Accepted by European Medicines Agency

Source from : Finanznachrichten - 2 days ago

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts ...See details»

Is There An Opportunity With Biogen Inc.'s (NASDAQ:BIIB) 26% Undervaluation?

Source from : Yahoo! Sports - 24 days ago

In this article we are going to estimate the intrinsic value of Biogen Inc. (NASDAQ:BIIB) by taking the forecast future cash flows of the company and discounting them back to today's value.See details»